CrunchBase is hiring! Check out our open positions →
Register | Login or Login

General Information

CategoryBioTech
Employees
Founded2011

Offices

Southport, USA
167 Old Post Road
Southport, CT, 06890
USA

Funding

TOTAL $1.74M
FUNDING TOTAL $1.74M
Seed, 8/11
Stonehenge Capital
Connecticut Innovations
$1.74M

Tags

Thetis Pharmaceuticals

Thetis Pharmaceuticals LLC is a bio-pharmaceutical company creating innovative chemistry and regulatory strategies in the development of prescription drugs in the Omega-3 arena.

The Company has three differentiated and IP-protected drug candidates at varying stages of development: TP-101 for the treatment of type 2 diabetes, TP-943 for the treatment of hypertriglyceridemia and mixed dyslipidemia, and TP-721 for the prevention and treatment of atrial fibrillation.

The key innovation underlying Thetis’ drug portfolio revolves around pharmaceuticalizing Omega-3 poly- unsaturated fatty acids into solid, water-soluble, new chemical entities (NCEs). This technology creates NCEs that instantaneously dissociate in aqueous media to deliver known entities in either a superior or targeted manner. Since the delivered entities are known drugs with excellent safety profiles, the Company expects to bypass many pre-clinical and clinical safety requirements and seek expedited registration in the U.S. Furthermore these novel chemical compounds have excellent prospects for superiority over existing Omega-3 drugs.

Recent Milestones

Videos

Screenshots

Sources

  1. Connecticut's Thetis Pharmaceuticals gains $1.5M seed investment (masshightech.com) [edit]
Edit This Page
Last Edited 9/15/12

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy